This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Innovation Observatory > Reports > Drugs > Granexin Gel for Diabetic Foot Ulcers

< Back

Granexin Gel for Diabetic Foot Ulcers



June 2018

Diabetes mellitus can cause serious foot problems as a result of diabetic neuropathy (loss of normal nerve function) and peripheral vascular disease (loss of normal circulation). These two conditions can lead to diabetic foot ulcers, as the nerves that usually carry pain sensation to the brain from the feet do not function as well and it is possible for unintentional foot damage to occur. Wearing tight shoes, cuts, blisters and bruises can all develop into diabetes foot ulcers. In a person with diabetes, a foot ulcer is defined as a patch of broken skin usually on the lower leg or feet. Diabetic foot ulcers can affect people with both type 1 and type 2 diabetes.
When blood sugar levels are high or fluctuate regularly, as in people with diabetes, skin that would normally heal may not properly repair itself because of nerve damage. As a result, even a mild injury can start a foot ulcer. Granexin gel contains the peptide ACT1, which possesses potential anti-inflammatory and regenerative properties when administered topically to diabetic foot ulcers. If licensed, granexin gel may offer an additional therapy option for diabetic foot ulcers which are a particularly difficult-to-treat chronic wound type.

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment

Download Full Article


Connect to the Innovation Observatory


Load More Related Posts

Get Alerts